SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Fancy who wrote (5166)8/17/1998 2:30:00 PM
From: Vector1  Read Replies (1) of 6136
 

AIDS DRUGS -
PROTEASE INHIBITORS +4% 100.0% 100.0%
Crixivan (Merck) -17% 32.1% 32.7%
Invirase (Roche) -67% 7.1% 7.3%
Viracept (Agouron) +27% 32.1% 32.4%
Norvir (Abbott) +45% 14.3% 14.3%
Fortovase (Roche) N.M. 12.5% 13.4%
ANALYSIS: Scripts for the class slowed to 4% in July. Roche's
new entry Fortovase (soft gel Invarase with better bioavailability)
gained share at the expense of its own Invirase. Agouron's Viracept
fell 0.3% share, but continues to close in on Merck's Crixivan.

AIDS DRUGS -
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News